Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis

Background: Most patients with moderate and severe chronic obstructive pulmonary disease (COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however, unclear if and what drug treatments should be added to LABAs to reduce exacerbations, which is an important goal of COPD management. Since current guidelines cannot make strong recommendations yet, our aim was to determine the relative efficacy of existing treatments and combinations to reduce the risk for COPD exacerbations. Methods: We included randomized clinical trials (RCTs) evaluating long-acting β2 agonists (LABA), long-acting muscarinic antagonists (LAMA), inhaled glucocorticosterioids (ICS), and the phosphodiesterase-4 (PDE4) inhibitor roflumilast, and combinations of these interventions in moderate to severe COPD populations. Our primary outcome was the event rate of exacerbations. We conducted a random-effects Bayesian mixed-treatment comparison (MTC) and applied several sensitivity analyses. In particular, we confirmed our findings using a binomial MTC analysis examining whether a patient experienced at least one exacerbation event or not during the trial. We also used an additive assumption to calculate the combined effects of treatments that were not included in the systematic review. Results: Twenty-six studies provided data on the total number of exacerbations and/or the mean annual rate of exacerbations among a combined 36,312 patients. There were a total of 10 treatment combinations in the MTC and 15 in the additive analysis. Compared with all other treatments, the combination of roflumilast plus LAMA exhibited the largest treatment effects, and had the highest probability (45%) of being the best first-line treatment. This was consistent whether applying the incidence rate analysis or the binomial analysis. When applying the additive assumption, most point estimates suggested that roflumilast may provide additional benefit by further reducing exacerbations. Conclusions: Using various meta-analytic approaches, our study demonstrates that depending on the choice of drug, combined treatments offer a therapeutic advantage.

[1]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[2]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[3]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[4]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[5]  A. Anzueto,et al.  Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.

[6]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[7]  R. Stockley,et al.  Addition of salmeterol to existing treatment in patients with COPD: a 12 month study , 2006, Thorax.

[8]  T. Wilt,et al.  Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline , 2007, Annals of Internal Medicine.

[9]  M. Littner,et al.  Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[10]  A Whitehead,et al.  Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.

[11]  D. D. Briggs,et al.  The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. , 2000, Chest.

[12]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[13]  D. Postma,et al.  Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. , 2009, Annals of internal medicine.

[14]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[15]  R. Buhl,et al.  Efficacy of tiotropium bromide (Spiriva®) in patients with chronic obstructive pulmonary disease (COPD) of different severities , 2006, Pneumologie.

[16]  B. Celli,et al.  Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). , 2003, Respiratory medicine.

[17]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[18]  E. Bateman,et al.  Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.

[19]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[20]  P. Barnes.  Chronic Obstructive Pulmonary Disease: A Growing but Neglected Global Epidemic , 2007, PLoS medicine.

[21]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[22]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[23]  S. Rennard,et al.  Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.

[24]  Keith Abrams,et al.  Use of Indirect and Mixed Treatment Comparisons for Technology Assessment , 2012, PharmacoEconomics.

[25]  Nicola J Cooper,et al.  Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. , 2006, Archives of internal medicine.

[26]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[27]  C. White,et al.  Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. , 2008, Clinical therapeutics.

[28]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[29]  Lucas M Bachmann,et al.  Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis , 2009, BMC Medicine.

[30]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[31]  C. Vogelmeier,et al.  Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. , 2008, Respiratory medicine.

[32]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[33]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[34]  P. Burge,et al.  A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[36]  L. Fabbri,et al.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[37]  R. Negro,et al.  Salmeterol & Fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline , 2003 .

[38]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[39]  John Ioannidis,et al.  Exploring the Geometry of Treatment Networks , 2008, Annals of Internal Medicine.

[40]  P. Calverley,et al.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.

[41]  S. Sahn,et al.  Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. , 2007, Clinical therapeutics.

[42]  S. Suissa.  Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[43]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[44]  N. Anthonisen,et al.  Contemporary management of chronic obstructive pulmonary disease: scientific review. , 2003, JAMA.

[45]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[46]  P. Jeffery,et al.  The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. , 2002, American journal of respiratory and critical care medicine.

[47]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[48]  N. Hanania,et al.  The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. , 2003, Chest.

[49]  F. Maltais,et al.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[50]  Nicky J Welton,et al.  Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. , 2009, American journal of epidemiology.

[51]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[52]  R. Goldstein,et al.  The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.

[53]  D. Price,et al.  Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study , 2007, Respiratory research.

[54]  M. Biraghi,et al.  Efficacy of Nebulized Flunisolide Combined with Salbutamol and Ipratropium Bromide in Stable Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease , 2006, Respiration.

[55]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[56]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[57]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[58]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[59]  F. Bart,et al.  The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease , 2006, Respiration.

[60]  B. Celli,et al.  Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. , 2006, Chest.

[61]  P. Moayyedi.  Meta-analysis: Can We Mix Apples and Oranges? , 2004, The American Journal of Gastroenterology.

[62]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[63]  T. Bengtsson,et al.  Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study , 2002, European Respiratory Journal.

[64]  N. Zhong,et al.  The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. , 2007, Chest.

[65]  C. Micheletto,et al.  Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. , 2003, Pulmonary pharmacology & therapeutics.

[66]  F. Martinez,et al.  Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD , 2011, Respiratory research.

[67]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[68]  I. Pavord,et al.  Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. , 2006, American journal of respiratory and critical care medicine.

[69]  Erica L. Baker,et al.  Pharmacologic Treatments for Chronic Obstructive Pulmonary Disease: A Mixed‐Treatment Comparison Meta‐analysis , 2009, Pharmacotherapy.

[70]  R. Zuwallack,et al.  Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[71]  J. Bourbeau,et al.  Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. , 1998, Thorax.

[72]  D. Niewoehner,et al.  Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.

[73]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[74]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[75]  T. Perez,et al.  Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[76]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[77]  R. Stockley,et al.  Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. , 1996, American journal of respiratory and critical care medicine.

[78]  S. Kesten,et al.  Absence of Electrocardiographic Findings and Improved Function with Once‐Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease , 2005, Pharmacotherapy.

[79]  W. Hop,et al.  Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.

[80]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[81]  D. Dusser,et al.  The effect of tiotropium on exacerbations and airflow in patients with COPD. , 2006, The European respiratory journal.

[82]  K. Rabe,et al.  Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. , 2005, Respiratory medicine.

[83]  G. Donaldson,et al.  Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. , 2008, Revista portuguesa de pneumologia.

[84]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.